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Abstract (258 words) 
Background. Exosomes are nanometer-sized vesicles released from cells into the blood, 
where they can transmit signals throughout the body. Exosomes have been shown to act on 
the heart, but their composition and the signaling pathways that they activate have not been 
explored. We hypothesized that endogenous plasma exosomes can communicate signals to 
the heart and provide protection against ischemia and reperfusion injury. 
Objectives. I) To isolate and characterize exosomes from rats and healthy volunteers. II) To 
evaluate the cardioprotective actions of plasma exosomes and to identify the molecular 
mechanisms involved. 
Methods: The exosome-rich fraction was isolated from the blood of adult rats and human 
volunteers and analyzed by protein marker expression, transmission electron microscopy 
and nanoparticle tracking analysis. This was then used in ex vivo, in vivo and in vitro settings 
of ischemia-reperfusion and the protective signaling pathways activated on cardiomyocytes 
were identified using Western blot analyses and chemical inhibitors. 
Results: Exosomes exhibited the expected size, and expressed marker proteins CD63, 
CD81 and HSP70. The exosome-rich fraction was powerfully cardioprotective in all tested 
models of cardiac ischemia-reperfusion injury. We identified a pro-survival signaling pathway 
activated in cardiomyocytes involving toll-like receptor 4, ERK1/2 and p38 MAPK, leading to 
activation of the cardioprotective protein HSP27. Cardioprotection was prevented by a 
neutralizing antibody against a conserved HSP70 epitope expressed on the exosome 
surface and by blocking TLR4 in cardiomyocytes, identifying the HSP70/TLR4 
communication axis as a critical component in exosome-mediated cardioprotection.  
Conclusion. Exosomes deliver endogenous protective signals to the myocardium by a 
pathway involving TLR4 and classic cardioprotective HSPs. 
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Introduction 
In recent years, immense interest has developed regarding the potential for extracellular 
vesicles to be used as therapeutic agents or as biomarkers of pathological states such as 
cardiovascular disease or cancer (1,2). In particular, exosomes have been proposed to 
stimulate beneficial signaling pathways in cardiovascular disease (1), for example, 
potentially mediating the pro-angiogenic actions of human stem cells (3). Exosomes can 
ferry miRNAs and proteins through the bloodstream and represent a potential mode of 
intercellular communication throughout the entire circulatory system (4). They are only 50-
100 nm in diameter, which renders them invisible to standard flow cytometry techniques, and 
necessitates ultracentrifugation for their purification.  
Therapeutically, exosomes appear to mediate many of the beneficial properties of stem cells 
administered to the heart (5,6). These studies have mainly focused on the role of exogenous 
exosomes administered to the heart, but not on endogenous exosomes, which are present in 
the blood of humans and rodents in the order of 1010 exosomes per ml (7). These striking 
numbers raise a crucial question as to their role. 
Obstruction of a coronary artery results in myocardial ischemia. The mainstay of clinical 
treatment is myocardial reperfusion, although this paradoxically causes further lethal injury 
—called myocardial reperfusion injury— for which there is, as yet, no effective clinical 
therapy (8). Heat shock proteins (HSPs) are powerfully cardioprotective (9-11), but clinical 
translation unfortunately faltered due to lack of practical techniques for their induction or 
delivery. After myocardial infarction, large elevations in serum HSP70 can stimulate 
inflammatory cytokine release via toll-like receptor 4 (TLR4) and the innate immune 
response (12,13). However, more mild stimulation of innate immunity via TLR ligands is 
necessary for myocardial preconditioning and cardioprotection (14,15). This raises the 
possibility that delivery of moderate levels of HSP70 could be beneficial. In addition to these 
effects of circulating HSP70, other families of HSP can mediate protection within the cell. For 
example, the small HSP27 (HSPB1), is required for optimal protection against ischemia and 
reperfusion injury (16,17).  
We hypothesized that endogenous exosomes communicate signals to the heart to protect it 
against ischemia and reperfusion injury. Furthermore, since recent evidence suggests that 
microvesicles can transfer protection by remote ischaemic preconditioning (RIC) (18), we 
hypothesized that RIC would augment exosome production, and thereby stimulate 
cardioprotection. We purified, characterized, and quantified exosomes from the plasma of 
rats and humans, and showed that they protect rat cardiomyocytes or hearts subject to 
ischemia and reperfusion both in vitro and in vivo. Cardioprotection was found to be 
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mediated by HSP70 on exosomes, which activated a pathway downstream of TLR4 
involving the kinases ERK1/2 and p38MAPK, and led to phosphorylation of HSP27.  
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Materials and Methods 
Animals were treated in accordance with the Animals (Scientific Procedures) act 1986 
published by the UK Home Office and the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health (Publication No. 85-23, revised 1996). The 
study of human samples was performed according to ethics approval reference 13/LO/0222 
and Declaration of Helsinki principles. Experimental details are provided in the Online 
Appendix. 
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Results 
Characterization and quantification of plasma exosomes 
The exosome-rich fraction was purified from the blood of adult male rats and healthy human 
male volunteers using a standard protocol of serial, differential centrifugation and 
ultracentrifugation steps. Using transmission electron microscopy (TEM) we observed the 
typical “cup-shaped” vesicles of exosomes that were <100 nm diameter for both rats and 
humans (Figure 1A).  
To characterize and quantify exosomes, we used the state-of-the-art technique of 
nanoparticle tracking analysis (NTA), which measures the number and size distribution of 
particles in purified, exosome-rich preparations. By NTA, the modal size of particles purified 
from control rat plasma was 75 ± 2 nm (Figure 1B, D), corresponding to the expected size of 
exosomes and the concentration was 0.1 ± 0.02 x 1011 ml-1 plasma (n=5 rats)(Figure 1C). 
The concentration of particles in the plasma of human volunteers was 6 ± 3 x 1011 ml-1 
(n=6)(Figure 1C), and their average modal size was 75 ± 7 nm (Figure 1D). For simplicity, 
we refer hereafter to the isolated particles as “exosomes”, although it should be noted that 
the isolated fraction also included some particles that were outside the expected size-range 
for exosomes. 
Next, we used flow cytometry to confirm the expression of marker proteins for exosomes in 
the human samples. The tetraspanin molecules CD63 and CD81 (found in many exosomes), 
as well as Heat Shock Protein 70 (HSP70), were all detectable at high levels (Figure 1E). 
Isotype control antibodies were negative (Supplementary Figure 1). Interestingly, the positive 
signal obtained using antibody clone cmHSP70.1, which specifically recognizes an epitope 
of HSP70 expressed on the surface of cells and exosomes (19,20), suggested that HSP70 is 
exposed on the surface of human exosomes (Figure 1E). 
We also performed SDS-PAGE and Western blot analyses to biochemically characterize the 
human samples, and were able to detect CD63, CD81 and, using either the antibody N27 or 
cmHsp70.1, HSP70 (Figure 1F). Similar results were obtained using rat exosomes 
(Supplementary Figure 2). 
Plasma exosomes are cardioprotective 
In order to investigate whether plasma exosomes are cardioprotective, we used four different 
experimental models. First, we used an in vivo rat model in which the entire exosome 
fraction isolated from a donor rat was administered to a naïve rat by i.v. tail vein injection, 15 
min prior to LAD occlusion. The area at risk was the same in each group (Supplementary 
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Figure 3A). The infarct size relative to the area at risk was reduced from 48 ± 5% (n=6) with 
vehicle, to 25 ± 6% (P<0.05, n=6), with exosomes (Figure 2A). Secondly, to exclude the 
influence of blood, Langendorff perfused rat hearts were exposed to all of the exosomes 
isolated from the blood of a donor rat during 15 min perfusion, before being subject to 35 min 
ischemia followed by 2 h reperfusion. The area at risk was the same in each group 
(Supplementary Figure 3B). The size of the infarct relative to the area at risk was 
significantly reduced from 35 ± 3% (n=6), to 22 ± 2% (P<0.01, n=10), by pre-treatment with 
rat exosomes (Figure 2B).  
Next, we used two in vitro cell models of cardiac cells to conduct simulated ischemia-
reperfusion, termed hypoxia-reoxygenation. Using the HL-1 cardiomyocyte cell line, and flow 
cytometry we analyzed cell death using double staining with the vital dye propidium iodide 
(PI) and the mitochondrial transmembrane potential (m)-sensitive dye DiOC6(3). After 
hypoxia-reoxygenation, 33 ± 8% of the live cells exhibited a low m – an early indicator of 
cell death – compared to 6 ± 4% in normoxia. The population of dead HL-1 cells was 45 ± 
9%, detected using PI, compared to 13 ± 5% in normoxia (Figure 2C). Pretreatment with rat 
exosomes significantly increased healthy cells from 20 ± 5% to 44 ± 7%, and reduced the 
population of cells with low m (24 ± 5%) as well as the PI+ve population of dead cells (30 ± 
6%) (Figure 2C). Protection was similar to that observed with insulin (27 ± 5% low m, 31 ± 
5% PI+ve), which is known to be protective in this model and was used as a positive control. 
These in vitro results were confirmed using primary adult rat cardiomyocytes as a more 
physiological model of cardiac cells, and in a dose response analysis. Hypoxia and re-
oxygenation increased cardiomyocyte cell death from 13 ± 3% to 59 ± 7% (n=5, 
P<0.001)(Figure 2D). The maximal tested dose of 109 exosomes per well was highly 
cardioprotective, reducing cell death to 17 ± 3%, similar to the effect of insulin, used as a 
positive control (14 ± 3% cell death) (Figure 2D). Significant protection remained evident 
down to a dose of 107 exosomes per well, at which dose control exosomes decreased death 
to 32 ± 8% (Figure 2D).  
Does manipulation of exosome concentration affect cardioprotection? 
If exosomes can activate cardioprotective pathways, this raises the possibility that 
manipulating their levels in the blood would have an impact on cardioprotection. As yet, no 
specific pharmacological inhibitors have been developed which can be used in vivo to 
decrease exosome production. However, it has recently been proposed that brief cycles of 
hind limb ischemia and reperfusion increase the number of extracellular vesicles (both 
exosomes and microvesicles) in the circulation (18). This manipulation, known as remote 
ischemic preconditioning or RIC, also renders the heart in a protected state (21,22).  
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We first examined whether RIC has any effect on plasma exosomes in humans subject to 
RIC. Exosomes were isolated from the same healthy volunteers both before and after a 
standard RIC procedure and characterized by NTA and TEM. RIC exosomes exhibited the 
same size and shape as control exosomes (Figures 1G-J), but importantly, their 
concentration in plasma was significantly increased after RIC (Figure 1H). Exosome 
concentration was similarly increased in rats after RIC, by both NTA and TEM 
(Supplementary Figure 4A).  
The ability of exosomes from RIC-treated rats to protect the heart was then determined. We 
observed that administration of RIC exosomes significantly decreased infarct size, both in 
vivo (Figure 2A) and in vitro (Figure 2B). We performed a complete dose-response curve 
comparing exosomes from control and RIC rats, using the in vitro model of hypoxia-
reoxygenation on primary cardiomyocytes. However, while there was a slight increase in 
protection with RIC exosomes, the difference was non-significant (Figure 2D). This 
suggested that, while exosomes after RIC remain cardioprotective and their numbers 
increase, this increase is insufficient to have a substantial effect on cardioprotection in this 
model. 
Exosomes trigger ERK and HSP27 activation in cardiomyocytes 
Next we studied the intracellular signaling pathways activated by exosomes on cardiac cells 
using Western blot analysis. The addition of rat exosomes to primary adult rat 
cardiomyocytes rapidly stimulated cardioprotective kinases. Phosphorylation of ERK1/2 was 
elevated by 2 min and maximal after 5 min exosome exposure, decreasing by 15 min (Figure 
3A). However, no increase in AKT phosphorylation was observed after exosome treatment, 
(Figure 3A), despite its phosphorylation by insulin. We conducted similar experiments with 
human exosomes and observed a very similar time-course of ERK1/2 phosphorylation with 
maximal phosphorylation after 5 min (Figure 3B). Again, no phosphorylation of AKT was 
detected in response to exosomes at any of the time-points, in contrast to the dual activation 
of ERK and AKT caused by insulin (Figure 3B). These results suggest that exosomes do not 
activate insulin receptor signaling. To further validate our results, we used human exosomes 
to stimulate HL-1 cardiomyocytes and once more, observed phosphorylation of ERK1/2 after 
5 min, without any effect on AKT (Supplementary Figure 5). The activation of ERK1/2 was 
tested in response to exosomes purified from four different human volunteers, and in each 
case, exosomes significantly stimulated ERK1/2 phosphorylation, by an average of 6.5 ± 1.0 
fold (P<0.05)(Figure 3C). 
To unequivocally confirm that ERK1/2 signaling was involved in the cardioprotection 
conferred by exosome treatment, cells were pre-incubated with 10 μM U0126 or 50 μM 
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PD98059, inhibitors of ERK1/2 signaling at the level of MEK. Both drugs completely inhibited 
ERK1/2 phosphorylation in response to human exosomes (Figure 3D), as well as eliminating 
cardioprotection in adult rat cardiomyocytes treated with human exosomes (Figure 3E). In 
control experiments the inhibitors alone had no effect (Supplementary Figure 6). 
One of the classic and highly cardioprotective effector proteins is the small HSP27 (16), 
regulated by phosphorylation at several serine residues. We tested a panel of antibodies 
recognizing these phospho-serine epitopes. Exposure of cardiomyocytes to human 
exosomes increased phosphorylation of HSP27 at all 3 sites relative to total levels of 
HSP27, or when measured relative to a housekeeping protein (Figure 4A). The clearest 
response was observed with phosphorylation of Ser78; therefore, this phosphorylation site 
was used in subsequent studies to define the signaling pathway leading to HSP27 
phosphorylation. 
HSP70 on the surface of exosomes mediates cardioprotection via TLR4/ERK/HSP27 
Given the rapid activation of ERK1/2 and HSP27 we suspected that a protein carried by the 
exosomes was interacting directly with a cell-surface receptor. However, in some cell types 
exosomes fuse with the membrane and deliver their contents intracellularly. In experiments 
using exosomes labelled with the fluorescent dye PKH67, no rat exosomes were taken up by 
primary adult rat cardiomyocytes even after 24 h exposure, despite them being taken up and 
visible intracellularly in 24 ± 7% of HUVEC cells after 1 h exposure (Supplementary Figure 
7). This suggested a direct interaction between an exosomal ligand and a cell surface 
receptor in cardiac myocytes. 
Extracellular HSP70 is considered to be a danger associated molecular pattern (DAMP), 
which can activate immune responses via binding to TLR4 (13,23). Our flow cytometry 
experiments had suggested that HSP70 is present on the surface of exosomes. This was 
confirmed by immuno-gold labeling using cmHsp70.1 and TEM of rat and human exosomes 
(Figure 4B). To neutralize this exosomal HSP70 we pre-incubated human exosomes with 
cmHSP70.1. This decreased their ability to stimulate phosphorylation of both ERK1/2 and 
HSP27-Ser78 (Figure 4C). Furthermore, these exosomes were no longer able to protect 
primary cardiomyocytes against hypoxia and re-oxygenation (Figure 4D). By itself, the 
neutralizing antibody did not affect cell survival (Figure 4D). 
Upstream of HSP27 phosphorylation, one of the most well established activators is the 
kinase p38MAPK. We used SB203580, an inhibitor of p38MAPKα/β and observed that 
HSP27 phosphorylation in response to exosomes was blocked, while leaving upstream 
ERK1/2 phosphorylation unaffected (Figure 5A). As shown above, U0126 blocked ERK1/2 
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phosphorylation, but also prevented phosphorylation of HSP27 (Figure 5A). These results 
suggest that ERK1/2 lies upstream of p38MAPK in the pathway.  
In order to establish a link between extracellular HSP70 and intracellular ERK1/2 and 
p38MAPK activation, we used TAK-242 to block intracellular signaling from TLR4. Pre-
treatment with TAK-242 decreased ERK1/2 phosphorylation in response to exosomes and 
blocked the phosphorylation of HSP27 (Figure 5A). Finally, we studied the effect of the 
whole pathway on the survival of cardiomyocytes subject to hypoxia-reoxygenation. Blocking 
TLR4, ERK1/2 or p38MAPK decreased the cardioprotective effect of exosome treatment 
(Figure 5B). 
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Discussion 
Previously considered as extracellular debris, it is only recently that exosomes have begun 
to be understood as vesicles communicating between cells. Several studies have shown that 
exosomes from cultured stem cells are cardioprotective (5,6). The present study focused on 
endogenous plasma exosomes. These were isolated from healthy rats and humans, and 
their identity confirmed by NTA, electron microscopy and biochemical detection of specific 
exosomal marker proteins (CD63, CD81 and HSP70). Plasma exosomes were found to be 
cardioprotective in an acute setting both in vitro and in vivo. This was mediated by exosomal 
HSP70 which stimulated TLR4 signaling, leading to the activation of ERK1/2, p38MAPK and 
subsequent HSP27 phosphorylation in cardiomyocytes (Figure 6).  
The origin of exosomes 
Plasma exosomes may originate from platelets, endothelium, erythrocytes, lymphocytes or 
other blood cells, but their origin is difficult to determine experimentally since, in contrast to 
microvesicles, exosomes do not necessarily express the same marker proteins as their 
parent cells (24).  
The increase in exosome number stimulated by RIC is interesting, but to date there are no 
tools available to prevent exosome release in vivo, therefore rigorous exclusion of the role of 
exosomes in RIC awaits the development of specific chemical inhibitors or knockout models. 
Alternatively, several other candidate proteins which may mediate RIC have also been 
proposed including SDF-1α (25) and Il-10 (26). 
The effect of exosomes on cardiomyocytes 
Although there is great interest of the potential for exosomes to deliver cargo inside various 
types of cells, there has been no prior examination of whether mature, adult cardiomyocytes 
are able to take up plasma exosomes. In fact, we were unable to detect any uptake of 
fluorescently labelled exosomes into primary cardiomyocytes even after 24 h incubation, 
despite their rapid uptake into endothelial cells. This, in combination with the rapidity of the 
signaling response activated by exosomes, and its dependence upon HSP70 on the 
exosome surface and on TLR4 signaling, strongly suggests that cardioprotection is mediated 
via direct ligand-receptor interaction on the cell surface. Since exosomes also contain other 
cargo such as miRNA, it will be interesting to determine whether they are also capable of 
delivering longer-term benefit via known cardioprotective miRNAs (27). 
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The protein kinase signaling pathways important for cardioprotection have been well 
described and include ERK1/2 and/or PI3K/AKT (8). Exosomes did not induce AKT but 
rapidly activated ERK1/2 phosphorylation by 5 min, and this was required for the induction of 
cardioprotection. There are a number of potential downstream targets of ERK1/2 including 
p38MAPK, which phosphorylates HSP27 (28). Inhibition of ERK1/2 with U0126 or of 
p38MAPK with SB203580 prevented phosphorylation of HSP27 corresponding with the loss 
of protection. SB203580 is specific to α and β isoforms of p38MAPK, which are also the two 
isoforms that are protective when transiently activated before ischemia (29). 
The link between Heat Shock Proteins and cardioprotection 
HSP27 is one of the most well-characterized members of the cardioprotective, small HSP 
family, and is highly expressed in the myocardium (16). In addition to controlling protein 
folding, small HSPs exert powerful protection against oxidative stress and apoptosis, and 
also maintain the structural integrity of the sarcomere (16,17). Strikingly, despite being well-
characterized and strongly activated in response to heat stress, no practical method of 
stimulating HSP27 phosphorylation has been developed and translated to the clinic. Our 
study shows for the first time that endogenous plasma exosomes are able to activate this 
HSP. 
We previously developed a neutralizing antibody against the highly conserved, exposed C-
terminal of HSP70 (19), and demonstrated that it blocks the immunosuppressive signaling 
pathways stimulated by exosomal HSP70 in myeloid-derived suppressor cells (20). We show 
here that neutralizing HSP70 on exosomes prevents their protective actions in 
cardiomyocytes including ERK1/2 and HSP27 phosphorylation. Heat shock proteins, 
including HSP27 and HSP70, are intracellular chaperones important for correct protein 
homeostasis. HSP70 is secreted from cells by exosomes (30), and is present in the serum of 
healthy individuals (31). In addition to the intracellular protective role of HSP70, recognized 
over 20 years ago, an intriguing new, extracellular role is emerging for HSP70. For instance, 
it was recently demonstrated that supporting cells in the inner ear can secrete HSP70 to 
protect hair cells from cell death in response to ototoxic drugs (32). Plasma HSP70 is 
believed to play a role in the activation of the adaptive and innate immune response (33). 
Interestingly, circulating HSP70 is elevated in patients with heart failure and can contribute to 
the disease by stimulating inflammatory cytokine release (13). Although activation of the 
innate immune system is generally regarded as being detrimental to the heart, a small 
degree of activation is protective (15), which is highly reminiscent of the manner in which sub 
lethal episodes of ischemia are protective during ischemic preconditioning. Importantly, mice 
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lacking TLR4 have been found to be resistant to the beneficial effects of preconditioning 
(14,15). Our data suggests that exosomal HSP70 can activate protective pathways in 
cardiomyocytes via TLR4, part of the evolutionarily ancient, innate immune system 
response. 
Limitations 
 
A limitation of our study is that it is not currently possible to achieve complete purity of 
exosomes from plasma, and consequently, significant amount of proteins and protein 
aggregates may still be present in the isolated fraction. We performed TEM to confirm the 
presence of HSP70 on the exosomal surface, and confirmed the lack of significant endotoxin 
contamination, but cannot exclude that non-exosomal HSP70 may be involved, or that other 
known inducers of TLRs (e.g.: CRP, ceruloplasmin) are present. Since TAK-242 did not 
entirely block ERK1/2 phosphorylation by exosomes, it is possible either that TLR4 was 
incompletely inhibited by TAK-242, or that ERK1/2 can also be partially activated an 
alternative, parallel route such as TLR2. Furthermore, since exosome isolation from 
biological fluids is quite difficult (34), accurate assessment of plasma exosome concentration 
before and after RIC awaits improved technology permitting their direct measurement. We 
did not quantify the increase in exosome concentration in animals after exosome 
administration in order to confirm a mass-action effect of exosomes. Since a larger quantity 
of blood was used to isolate exosomes from humans than rats, and an additional 
ultracentrifugation step was included to obtain an exosome fraction of comparable purity, a 
direct comparison cannot be made between rat and human exosomes. All samples were 
compared to vehicle, which could potentially have influenced results. 
Conclusion 
In conclusion, given that plasma exosomes are cardioprotective, these nanoparticles are 
worthy of further investigation as they may represent a new frontier in our search for ways to 
protect the myocardium at risk of severe injury. 
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Perspectives 
Competency in medical knowledge: Exosomes - long considered extracellular debris - are 
increasingly recognized as endogenous vesicles with signalling roles. Plasma exosomes are 
shown to activate cardioprotective signalling pathways culminating in phosphorylation of 
HSP27. This highlights their role as newly identified endocrine signalling molecules. 
Translational outlook: Exosomes isolated from plasma have the potential to be used as 
therapeutic agents to activate endogenous protective mechanisms. Further work is required 
to develop simpler methods for their isolation and purification, and to understand the 
pathways regulating their release and distribution. 
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Figure legends 
 
Figure 1. Characterization and quantification of plasma exosomes. (A) Electron micrographs 
of purified exosomes from rats and humans. Bar: 100 nm. (B) Representative results of 
nanoparticle tracking analysis (NTA) demonstrate similar size distribution in diluted samples 
of human and rat exosomes. (C, D) Average concentration and size of exosomes in plasma 
(n=5 rats, n=6 humans). (E) Flow cytometry analysis of microspheres coated with exosome-
rich fractions isolated from humans (see Materials and Methods for details) identified the 
presence of exosomal markers CD63, CD81 and HSP70, both at baseline (control, black), 
and after remote ischemic preconditioning (RIC, red). Strong staining was also observed 
using antibody cmHsp70.1, specific to an external epitope of HSP70. The yellow curve 
indicates exosome-coated microspheres stained with secondary antibodies as a control. 
Isotype controls are shown in Supplementary Figure 1. (F) Western blots confirmed the 
presence of exosomal marker proteins CD63, CD81 and HSP70 in human samples. Levels 
of all proteins were increased after remote ischemic conditioning (RIC) (*P<0.05, n=3). (G) 
(H-K) The size distribution and concentration of human exosomes as determined by TEM 
(H) and NTA (I), before and after RIC. Average modal size of exosomes was unaltered by 
RIC (n=6). Plasma concentration of exosomes increased after RIC (**P<0.01, n=6).  
 
Figure 2. Purified plasma exosomes are cardioprotective. (A) Exosomes purified from a 
control donor rat or a donor rat subject to remote ischemic preconditioning (RIC), and 
administered via tail vein injection into a naive rat decreased infarct size (as percentage of 
area at risk AAR), in an in vivo model of reperfusion injury. Protection was similar when RIC 
was applied to the rat hindlimb in vivo (in vivo RIC)(**P<0.01,n=6). (B) Exosomes purified 
from a control rat, or one subject to RIC, decreased infarct size (as percentage of area at 
risk AAR), in an isolated, Langendorff perfused rat heart model of reperfusion injury 
(**P<0.01,n=6-9). (C) Flow cytometry analysis shows that HL-1 cardiomyocytes were 
protected against hypoxia and reoxygenation by pre-incubation with plasma exosomes from 
rats, as determined by DiOC6(3) and propidium iodide  staining (n=3). Insulin was used as a 
positive control. The quadrants include mean ± SEM percentage values from at least three 
independent experiments. (D) Pre-incubation with rat exosomes decreased death in primary 
adult rat cardiomyocytes subject to hypoxia and reoxygenation. Cells were imaged by phase 
contrast and red fluorescence to visualize propidium iodide. Representative images are 
shown from cells in conditions of normoxia, hypoxia/reoxygenation (Hypox/Reox), with the 
addition of 109 exosomes/well, or insulin as a positive control, as indicated. A dose-response 
curve was performed with 105 to 109 control or RIC exosomes/well and compared to insulin 
(ins). (*P<0.05; **P<0.01 vs. Hypox/reox alone; n=6). Scale bar 100 μm. 
 
Figure 3. Rat plasma exosomes activate the ERK1/2 signaling pathway in cardiomyocytes. 
(A) Western blot analysis of adult rat cardiomyocytes shows robust and rapid activation of 
ERK1/2 after stimulation with rat plasma exosomes. AKT was not activated (insulin is 
included as a positive control). (n = 3 independent experiments). (B) Similarly, ERK1/2 but 
not AKT was phosphorylated in adult rat cardiomyocytes after exposure to human plasma 
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exosomes (n = 3 independent experiments). (C) Human plasma exosomes isolated from 4 
different individuals activated ERK1/2 phosphorylation after stimulation of adult rat 
cardiomyocytes for 5 min (quantified on the lower graph). (D) Preincubation (15 min) with the 
inhibitors of ERK1/2 phosphorylation, U0126 and PD98059, prevented phosphorylation of 
ERK1/2 in adult rat cardiomyocytes stimulated with human exosomes for 5 min (n = 3 
independent experiments). (E) Experiments using adult rat cardiomyocytes subjected to 
hypoxia/reoxygenation show that U0126 and PD98059 blocked protection by human 
exosomes, n=3. *P<0.05 and **P<0.01 vs. 0’ time point (panels A-B), vs. control (panel C), 
or vs. normoxia (panel E). 
 
Figure 4. HSP70 on the surface of exosomes mediates ERK1/2 and HSP27 
phosphorylation, as well as cardioprotection in response to exosomes. (A) Treatment of 
adult rat cardiomyocytes with human exosomes activates HSP27 phosphorylation at 
different serine epitopes; n = 3, *P<0.05; **P<0.01 vs control conditions. (B) Electron 
microscopy (TEM) of rat exosomes immunostained with cmHsp70.1 demonstrates the 
presence of HSP70 on exosomal surface both before and after remote ischemic 
preconditioning (RIC) (black dots are 5 nm gold particles). (C) Neutralization of exosomal 
HSP70 by cmHSP70.1 blocks the phosphorylation of ERK1/2 and HSP27-Ser78 in adult rat 
cardiomyocytes stimulated with exosomes for 5 min; n = 3, **P<0.01 over untreated cells; 
##P<0.01 over exosomes. (D) Neutralization of exosomal HSP70 by cmHSP70.1 blocks the 
protection of adult rat cardiomyocytes in response to exosomes. Scale bar 100 μm. 
Experiments are shown as mean ± SEM, n = 3. **P<0.01, as indicated, n.s. = non 
significant. 
 
Figure 5. Exosomes activate TLR4 to trigger ERK- and p38MAPK-dependent induction of 
HSP27. (A) Inhibitors of TLR4 (TAK-242), ERK1/2 (U0126), or p38MAPK (SB203580) block 
the phosphorylation of both ERK1/2 and HSP27-Ser78 in response to exosomes. On their 
own, TAK-242 and SB203580 increased slightly ERK1/2 phosphorylation, but there was no 
activation of HSP27. n = 3; **P<0.01 vs. vehicle; ##P<0.01 vs. exosomes. (B) The above 
inhibitors blocked protection by exosomes on adult rat cardiomyocytes subjected to 
hypoxia/reoxygenation; n = 3; **P<0.01 as indicated, n.s. = non significant. Scale bar 100 
μm. 
 
Figure 6. Proposed mechanism, whereby HSP70 in exosomes stimulates TLR4 in cells, 
leading via ERK1/2 and p38MAPK to phosphorylation of HSP27 and cardioprotection. We 
hypothesize that other exosomal signals may lead alternatively to acute or delayed 
cardioprotection. 
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